DFTX
Definium Therapeutics, Inc.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Neutral
+13/100
Last price
35.90
▲ 0.28 (0.79%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
35.50
Prev close
35.62
Day high
36.39
Day low
35.09
Volume
497.51K
Market cap
$4.82B
P/E (TTM)
—
52W range
10.47 – 49.70
Day trading desk
Gap from prior close
-0.34%
Prior close 35.62
VWAP
35.89
+0.02% from price
Relative volume
0.23×
Quiet session
Session range
3.69%
35.09 – 36.39
Position in range
63%
Mid range
ATR (14D)
1.75
4.89% of price
Prior day high
36.55
PDH
Prior day low
34.38
PDL
Bid / ask spread
—
Quote not published
Session volume
494.26K
Avg 2.15M
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-5.68%
-7.2%
1M
-6.09%
-7.2%
3M
-25.90%
-28.9%
6M
+70.79%
+56.2%
YTD
+168.11%
+154.5%
1Y
+193.78%
+178.5%
3Y
+1,073.20%
+991.9%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on DFTX open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+2.57M
Net buying
Buy transactions
21
2.71M shares
Sell transactions
11
140.08K shares
Net transactions
+32
Buys less sells
Sell : buy shares
0.1 : 1
Mixed
Insider-held shares
3.45M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 25, 26 | SULLIVAN MARK R Officer |
SELL | 14.05K | $513.85K | Direct |
| Sep 25, 26 | ROBERTS BRANDI L Chief Financial Officer |
SELL | 3.38K | $123.50K | Direct |
| Sep 25, 26 | WILEY MATTHEW T Officer |
SELL | 3.10K | $113.26K | Direct |
| Sep 25, 26 | BARROW ROBERT B Chief Executive Officer |
SELL | 31.55K | $1.15M | Direct |
| Sep 25, 26 | KARLIN DANIEL ROLLINGS Officer and Director |
SELL | 10.85K | $396.89K | Direct |
| Sep 14, 26 | SULLIVAN MARK R Officer |
STOCK | 125.00K | $0 | Direct |
| Sep 14, 26 | ROBERTS BRANDI L Chief Financial Officer |
STOCK | 125.00K | $0 | Direct |
| Sep 14, 26 | WILEY MATTHEW T Officer |
STOCK | 125.00K | $0 | Direct |
| Sep 14, 26 | BARROW ROBERT B Chief Executive Officer |
STOCK | 750.00K | $0 | Direct |
| Sep 14, 26 | KARLIN DANIEL ROLLINGS Officer |
STOCK | 200.00K | $0 | Direct |
| Sep 3, 26 | BARROW ROBERT B Chief Executive Officer |
SELL | 19.02K | $721.73K | Direct |
| Sep 2, 26 | BARROW ROBERT B Chief Executive Officer |
STOCK | 40.00K | $0 | Direct |
| Aug 12, 26 | SULLIVAN MARK R Officer |
STOCK | 62.50K | $0 | Direct |
| Aug 12, 26 | ROBERTS BRANDI L Chief Financial Officer |
STOCK | 62.50K | $0 | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BARROW ROBERT B |
Chief Executive Officer | 2.21M | Sale |
BRUHN SUZANNE LOUISE |
Director | 24.29K | Stock Award(Grant) |
CRYSTAL ROGER |
Director | 24.29K | Stock Award(Grant) |
GRYSKA DAVID W |
Director | 19.90K | Stock Award(Grant) |
KARLIN DANIEL ROLLINGS |
Officer and Director | 792.85K | Sale |
KREBS ANDREAS |
Director | 19.77K | Stock Award(Grant) |
LIAO CARRIE FENG JU |
Officer | 144.92K | Sale |
ROBERTS BRANDI L |
Chief Financial Officer | 394.53K | Sale |
SULLIVAN MARK R |
Officer | 494.23K | Sale |
WILEY MATTHEW T |
Officer | 359.04K | Sale |
Fundamentals
Market cap$4.82B
Enterprise value$3.74B
Revenue (TTM)—
Gross profit—
EBITDA—
Net income$-353.78M
EPS (TTM)$-3.43
Free cash flow$7.61M
Total cash$1.08B
Total debt$36.47M
Book value / share$6.84
Shares outstanding134.37M
Float125.17M
Short % of float8.83%
Dividend yield0.00%
Beta (5Y)2.19
Valuation & profitability ratios
Trailing P/E—
Forward P/E-18.87
PEG ratio—
Price / sales—
Price / book5.25
EV / revenue—
EV / EBITDA—
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity-64.09%
Return on assets-20.64%
Debt / equity3.97
Current ratio6.95
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | — | — |
| Operating revenue | $0 | $0 | $0 | $0 | — | — |
| Research & development | $117.67M | $65.30M | $52.12M | $36.17M | — | +80.2% |
| Selling, general & admin | $48.64M | $38.62M | $41.74M | $30.16M | — | +26.0% |
| Total operating expense | $166.31M | $103.92M | $93.87M | $66.33M | — | +60.0% |
| Operating income | -$166.31M | -$103.92M | -$93.87M | -$66.33M | — | -60.0% |
| Net interest income | $5.48M | $9.28M | $4.66M | $1.50M | — | -40.9% |
| Pre-tax income | -$183.79M | -$108.68M | -$95.73M | -$56.80M | — | -69.1% |
| Tax provision | — | — | — | $0 | -$1.16M | — |
| Net income | -$183.79M | -$108.68M | -$95.73M | -$56.80M | — | -69.1% |
| Net income to common | -$183.79M | -$108.68M | -$95.73M | -$56.80M | — | -69.1% |
| Basic EPS | -2.06 | -1.54 | -2.44 | -1.84 | — | -33.8% |
| Diluted EPS | -2.06 | -1.54 | -2.44 | -1.84 | — | -33.8% |
| EBIT | -$178.31M | -$106.40M | -$94.81M | -$66.33M | — | -67.6% |
| EBITDA | -$178.31M | -$105.87M | -$91.65M | -$63.15M | — | -68.4% |
| Basic shares | 89.33M | 70.46M | 39.16M | 30.86M | — | +26.8% |
| Diluted shares | 89.33M | 70.46M | 39.16M | 30.86M | — | +26.8% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $257.84M | $273.74M | $99.70M | $142.14M | -5.8% |
| Cash & short-term investments | $411.59M | $273.74M | $99.70M | $142.14M | +50.4% |
| Total current assets | $419.32M | $281.62M | $103.87M | $146.06M | +48.9% |
| Goodwill & intangibles | $19.92M | $19.92M | $20.45M | $23.61M | 0.0% |
| Total assets | $440.10M | $302.15M | $124.54M | $169.99M | +45.7% |
| Total current liabilities | $66.70M | $38.85M | $32.25M | $17.89M | +71.7% |
| Long-term debt | $40.58M | $21.85M | $14.13M | — | +85.7% |
| Total debt | $40.58M | $21.85M | $14.13M | $72.00K | +85.7% |
| Total liabilities | $107.77M | $60.70M | $46.41M | $19.08M | +77.5% |
| Retained earnings | -$582.67M | -$398.88M | -$290.20M | -$194.47M | -46.1% |
| Shareholder equity | $332.33M | $241.45M | $78.13M | $150.92M | +37.6% |
| Working capital | $352.62M | $242.77M | $71.63M | $128.16M | +45.2% |
| Net tangible assets | $312.41M | $221.53M | $57.69M | $127.31M | +41.0% |
| Shares issued | 98.78M | 75.10M | 41.10M | 37.98M | +31.5% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$183.79M | -$108.68M | -$95.73M | -$56.80M | — | -69.1% |
| Depreciation & amortisation | $0 | $527.00K | $3.16M | $3.18M | — | -100.0% |
| Stock-based compensation | $20.10M | $16.91M | $15.18M | $13.71M | — | +18.8% |
| Change in working capital | $9.44M | -$3.34M | $6.28M | -$3.78M | — | +382.2% |
| Operating cash flow | -$131.56M | -$79.13M | -$64.36M | -$50.14M | — | -66.3% |
| Investing cash flow | -$151.61M | $0 | — | $0 | -$297.00K | — |
| Financing cash flow | $267.27M | $253.20M | $21.85M | $59.05M | — | +5.6% |
| Free cash flow | -$131.56M | -$79.13M | -$64.36M | -$50.14M | — | -66.3% |
| End cash position | $257.84M | $273.74M | $99.70M | $142.14M | — | -5.8% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Operating revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Research & development | $48.66M | $41.48M | $33.52M | $30.98M | $29.81M | — | +17.3% |
| Selling, general & admin | $26.41M | $17.74M | $14.06M | $14.69M | $11.09M | — | +48.9% |
| Total operating expense | $75.08M | $59.22M | $47.58M | $45.67M | $40.90M | — | +26.8% |
| Operating income | -$75.08M | -$59.22M | -$47.58M | -$45.67M | -$40.90M | — | -26.8% |
| Net interest income | $2.35M | $2.21M | $2.22M | $988.00K | $436.00K | — | +6.4% |
| Pre-tax income | -$158.99M | -$77.10M | -$50.44M | -$67.27M | -$42.74M | — | -106.2% |
| Net income | -$158.99M | -$77.10M | -$50.44M | -$67.27M | -$42.74M | — | -106.2% |
| Net income to common | -$158.99M | -$77.10M | -$50.44M | -$67.27M | -$42.74M | — | -106.2% |
| Basic EPS | -1.44 | -0.71 | — | -0.78 | -0.50 | -0.27 | -102.8% |
| Diluted EPS | -1.44 | -0.71 | — | -0.78 | -0.50 | -0.35 | -102.8% |
| EBIT | -$157.75M | -$75.85M | -$49.17M | -$65.99M | -$40.41M | — | -108.0% |
| EBITDA | -$157.75M | -$75.85M | -$49.17M | -$65.99M | -$40.41M | — | -108.0% |
| Basic shares | 110.68M | 108.79M | — | 85.89M | 85.35M | 85.07M | +1.7% |
| Diluted shares | 110.68M | 108.79M | — | 85.89M | 85.35M | 87.09M | +1.7% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $655.27M | $262.52M | $257.84M | $19.96M | $33.39M | +149.6% |
| Cash & short-term investments | $1.08B | $373.42M | $411.59M | $209.07M | $182.99M | +190.3% |
| Total current assets | $1.09B | $380.56M | $419.32M | $215.85M | $189.14M | +187.0% |
| Goodwill & intangibles | $19.92M | $19.92M | $19.92M | $19.92M | $19.92M | 0.0% |
| Total assets | $1.11B | $401.29M | $440.10M | $236.92M | $265.09M | +177.3% |
| Total current liabilities | $157.20M | $81.11M | $66.70M | $65.42M | $37.96M | +93.8% |
| Long-term debt | $36.47M | $40.77M | $40.58M | $40.38M | $41.19M | -10.6% |
| Total debt | $36.47M | $40.77M | $40.58M | $40.38M | $41.19M | -10.6% |
| Total liabilities | $194.22M | $122.44M | $107.77M | $106.32M | $79.69M | +58.6% |
| Retained earnings | -$818.76M | -$659.77M | -$582.67M | -$532.24M | -$464.97M | -24.1% |
| Shareholder equity | $918.68M | $278.85M | $332.33M | $130.60M | $185.40M | +229.5% |
| Working capital | $934.90M | $299.45M | $352.62M | $150.43M | $151.18M | +212.2% |
| Net tangible assets | $898.76M | $258.93M | $312.41M | $110.68M | $165.48M | +247.1% |
| Shares issued | 132.74M | 104.04M | 98.78M | 76.77M | 75.80M | +27.6% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | -$158.99M | -$77.10M | -$50.44M | -$67.27M | -$42.74M | — | -106.2% |
| Depreciation & amortisation | — | — | $0 | $0 | $0 | $0 | — |
| Stock-based compensation | $9.64M | $7.13M | $5.60M | $5.82M | $5.25M | — | +35.2% |
| Change in working capital | $6.28M | $5.45M | -$4.29M | $8.10M | $8.09M | — | +15.3% |
| Operating cash flow | -$52.78M | -$42.63M | -$42.98M | -$29.57M | -$29.60M | — | -23.8% |
| Investing cash flow | -$316.74M | $42.00M | $34.98M | $15.41M | -$39.54M | — | -854.1% |
| Financing cash flow | $762.27M | $5.31M | $245.87M | $749.00K | $19.65M | — | +14,258.0% |
| Free cash flow | -$52.78M | -$42.63M | -$42.98M | -$29.57M | -$29.60M | — | -23.8% |
| End cash position | $655.27M | $262.52M | $257.84M | $19.96M | $33.39M | — | +149.6% |
Options analytics
Put / call volume
0.28
Call-heavy session
Put / call open interest
0.66
Positioning, not flow
Max pain
40.00
+11.4% from spot
ATM implied vol
71.6%
Nearest strike to spot
Skew (10% OTM)
+20.4%
Puts bid over calls
Call volume
500
Contracts, this expiry
Put volume
138
Contracts, this expiry
Heaviest call OI
50.00
4.39K contracts
Heaviest put OI
37.00
3.14K contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.55 | -1.44 | -162.3% |
| Mar 2026 | -0.49 | -0.71 | -44.0% |
| Dec 2025 | -0.49 | -0.50 | -2.0% |
| Sep 2025 | -0.50 | -0.78 | -54.8% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.56 | 13 | $0 | 0.0% |
| Next quarter | -0.53 | 13 | $0 | 0.0% |
| Current year | -3.16 | 14 | $0 | 0.0% |
| Next year | -1.90 | 13 | $31.42M | 0.0% |
Analyst targets & ownership
Mean target$71.65
High target$91.00
Low target$55.00
Implied upside99.57%
Analyst count17
ConsensusNONE
Strong buy / Buy4 / 14
Hold0
Sell / Strong sell0 / 0
Held by insiders2.57%
Held by institutions88.44%
Institutions holding462
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
37.03
-3.06% from price
SMA 20
37.83
-5.10% from price
SMA 50
40.73
-11.86% from price
SMA 100
37.33
-3.84% from price
SMA 200
27.77
+29.29% from price
EMA 12
37.18
-3.45% from price
EMA 26
38.31
-6.29% from price
EMA 50
38.85
-7.58% from price
RSI (14)
39.2
Neutral
MACD (12,26,9)
-1.13
Hist -0.09
ATR (14)
1.75
4.89% of price
Realised vol 30D
49.3%
Annualised
Bollinger upper
40.44
20, 2σ
Bollinger lower
35.23
20, 2σ
50 / 200 cross
Golden
40.73 vs 27.77
Trend bias
Above 200
+29.29%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.02
More volatile than market
Correlation to SPY
0.17
Largely independent
Realised vol 30D
49.3%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-26.5%
Peak to trough
Max drawdown 5Y
-95.0%
Peak to trough
ATR 14
1.75
4.89% of price
Beta (reported)
2.19
5Y monthly, from filing
Short interest
Shares short
11.79M
Prior 8.97M
Change vs prior
+31.4%
Shorts adding
% of float
8.83%
Normal
% of shares out
8.77%
Against total outstanding
Days to cover
5.8
Crowded exit
Float
125.17M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 15, 26 | Canaccord Genuity | MAINTAINED | Buy | Buy |
| Sep 15, 26 | Baird | MAINTAINED | Outperform | Outperform |
| Sep 14, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Sep 14, 26 | Needham | MAINTAINED | Buy | Buy |
| Sep 11, 26 | RBC Capital | MAINTAINED | Outperform | Outperform |
| Aug 18, 26 | B of A Securities | INITIATED | — | Buy |
| Aug 14, 26 | Maxim Group | MAINTAINED | Buy | Buy |
| Aug 13, 26 | Jones Trading | MAINTAINED | Buy | Buy |
| Aug 13, 26 | Canaccord Genuity | MAINTAINED | Buy | Buy |
| Aug 13, 26 | RBC Capital | MAINTAINED | Outperform | Outperform |
| Aug 13, 26 | Wells Fargo | MAINTAINED | Overweight | Overweight |
| Aug 13, 26 | Baird | MAINTAINED | Outperform | Outperform |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay date—
Last split1:15
Split dateAug 29, 2022
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-09-14
Corporate Changes & Voting Matters
8-K · 2026-09-08
Corporate Changes & Voting Matters
8-K · 2026-08-12
Periodic Financial Reports
10-Q · 2026-08-06
Offering Registrations
S-8 · 2026-06-16
Corporate Changes & Voting Matters
8-K · 2026-06-12
Corporate Changes & Voting Matters
8-K · 2026-05-19
Corporate Changes & Voting Matters
8-K · 2026-05-12
Headlines
Jefferies Highlights Three Biotech Stocks With Blockbuster Potential
Investing.com · 7d ago
Definium Therapeutics Insider Sold Shares Worth $1,153,784, According to a Recent SEC Filing
MT Newswires · 7d ago
Definium Therapeutics Announces New Employee Inducement Grants
Business Wire · 9d ago
Definium Therapeutics Highlights Phase III DT120 Gains in Anxiety and Depression
MarketBeat · 13d ago
Weekly Roundup on the Cannabis Sector & Psychedelic Sector
Market Exclusive · 16d ago
Definium’s LSD Pill Clears a Second Anxiety Trial, and the Psychedelics Sector Is Watching
Insider Monkey · 17d ago
Definium Therapeutics’ DT120 Hits Phase III Goals in Anxiety Study
MarketBeat · 18d ago
Biotech Midweek Pulse: XBI Loses Steam After Hot 2026 Run — Here Are The Stocks And Catalysts To Watch Next
Stocktwits · 22d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.